Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 5/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29310128 | 1.00 | WEE1 (0.44) | WEE1MAP4K1LRRK2AXLBTK | |
| SCHEMBL29310127 | 0.89 | WEE1 (0.48) | WEE1MAP4K1AXLBTKPLK1 | |
| SCHEMBL30997668 | 0.89 | WEE1 (0.48) | WEE1MAP4K1AXLBTKPLK1 | |
| SCHEMBL30997619 | 0.88 | WEE1 (0.43) | WEE1LRRK2AXLBTKPLK1 | |
| SCHEMBL29310241 | 0.88 | WEE1 (0.43) | WEE1LRRK2AXLBTKPLK1 | |
| SCHEMBL29310234 | 0.80 | SLC2A1 (0.42) | WEE1MAP4K1LRRK2BTKPLK1 | |
| SCHEMBL30997656 | 0.79 | WEE1 (0.48) | WEE1SLC2A1SYKPKMYT1TNK2 | |
| SCHEMBL29310126 | 0.79 | WEE1 (0.48) | WEE1SLC2A1SYKPKMYT1TNK2 | |
| SCHEMBL29310355 | 0.78 | TYK2 (0.45) | WEE1MAP4K1TYK2SYKIDH1 | |
| SCHEMBL29310236 | 0.77 | BTK (0.49) | WEE1AXLBTKPLK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | WEE1 1/4885MAP4K1 866/4885LRRK2 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.